Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

International severe asthma registry (ISAR): protocol for a global registry

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

FitzGerald, JM, Tran, TN, Alacqua, M, Altraja, A, Backer, V, Bjermer, L, Bjornsdottir, U, Bourdin, A, Brusselle, G, Bulathsinhala, L, Busby, J, Canonica, GW, Carter, V, Chaudhry, I, Cho, YS, Christoff, G, Cosio, BG, Costello, RW, Eleangovan, N, Gibson, PG, Heaney, LG, Heffler, E, Hew, M, Hosseini, N, Iwanaga, T, Jackson, DJ, Jones, R, Koh, MS, Le, T, Lehtimäki, L, Ludviksdottir, D, Maitland-van der Zee, AH, Menzies-Gow, A, Murray, RB, Papadopoulos, NG, Perez-de-Llano, L, Peters, M, Pfeffer, PE, Popov, TA, Porsbjerg, CM, Price, CA, Rhee, CK, Sadatsafavi, M, Tohda, Y, Wang, E, Wechsler, ME, Zangrilli, J & Price, DB 2020, 'International severe asthma registry (ISAR): protocol for a global registry' BMC Medical Research Methodology, bind 20, nr. 1, s. 212. https://doi.org/10.1186/s12874-020-01065-0

APA

FitzGerald, J. M., Tran, T. N., Alacqua, M., Altraja, A., Backer, V., Bjermer, L., ... Price, D. B. (2020). International severe asthma registry (ISAR): protocol for a global registry. BMC Medical Research Methodology, 20(1), 212. https://doi.org/10.1186/s12874-020-01065-0

CBE

FitzGerald JM, Tran TN, Alacqua M, Altraja A, Backer V, Bjermer L, Bjornsdottir U, Bourdin A, Brusselle G, Bulathsinhala L, Busby J, Canonica GW, Carter V, Chaudhry I, Cho YS, Christoff G, Cosio BG, Costello RW, Eleangovan N, Gibson PG, Heaney LG, Heffler E, Hew M, Hosseini N, Iwanaga T, Jackson DJ, Jones R, Koh MS, Le T, Lehtimäki L, Ludviksdottir D, Maitland-van der Zee AH, Menzies-Gow A, Murray RB, Papadopoulos NG, Perez-de-Llano L, Peters M, Pfeffer PE, Popov TA, Porsbjerg CM, Price CA, Rhee CK, Sadatsafavi M, Tohda Y, Wang E, Wechsler ME, Zangrilli J, Price DB. 2020. International severe asthma registry (ISAR): protocol for a global registry. BMC Medical Research Methodology. 20(1):212. https://doi.org/10.1186/s12874-020-01065-0

MLA

Vancouver

Author

FitzGerald, J Mark ; Tran, Trung N ; Alacqua, Marianna ; Altraja, Alan ; Backer, Vibeke ; Bjermer, Leif ; Bjornsdottir, Unnur ; Bourdin, Arnaud ; Brusselle, Guy ; Bulathsinhala, Lakmini ; Busby, John ; Canonica, Giorgio W ; Carter, Victoria ; Chaudhry, Isha ; Cho, You Sook ; Christoff, George ; Cosio, Borja G ; Costello, Richard W ; Eleangovan, Neva ; Gibson, Peter G ; Heaney, Liam G ; Heffler, Enrico ; Hew, Mark ; Hosseini, Naeimeh ; Iwanaga, Takashi ; Jackson, David J ; Jones, Rupert ; Koh, Mariko S ; Le, Thao ; Lehtimäki, Lauri ; Ludviksdottir, Dora ; Maitland-van der Zee, Anke H ; Menzies-Gow, Andrew ; Murray, Ruth B ; Papadopoulos, Nikolaos G ; Perez-de-Llano, Luis ; Peters, Matthew ; Pfeffer, Paul E ; Popov, Todor A ; Porsbjerg, Celeste M ; Price, Chris A ; Rhee, Chin K ; Sadatsafavi, Mohsen ; Tohda, Yuji ; Wang, Eileen ; Wechsler, Michael E ; Zangrilli, James ; Price, David B. / International severe asthma registry (ISAR) : protocol for a global registry. I: BMC Medical Research Methodology. 2020 ; Bind 20, Nr. 1. s. 212.

Bibtex

@article{1453ba7ac3b34d1db789b99b01d27b32,
title = "International severe asthma registry (ISAR): protocol for a global registry",
abstract = "BACKGROUND: Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the heterogeneity of the severe asthma population, many patients need to be evaluated to understand the clinical features and outcomes of severe asthma in order to facilitate personalised and targeted care. The International Severe Asthma Registry (ISAR) is a multi-country registry project initiated to aid in this endeavour.METHODS: ISAR is a multi-disciplinary initiative benefitting from the combined experience of the ISAR Steering Committee (ISC; comprising 47 clinicians and researchers across 29 countries, who have a special interest and/or experience in severe asthma management or establishment and maintenance of severe asthma registries) in collaboration with scientists and experts in database management and communication. Patients (≥18 years old) receiving treatment according to the 2018 definitions of the Global Initiative for Asthma (GINA) Step 5 or uncontrolled on GINA Step 4 treatment will be included. Data will be collected on a core set of 95 variables identified using the Delphi method. Participating registries will agree to provide access to and share standardised anonymous patient-level data with ISAR. ISAR is a registered data source on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ISAR's collaborators include Optimum Patient Care, the Respiratory Effectiveness Group (REG) and AstraZeneca. ISAR is overseen by the ISC, REG, the Anonymised Data Ethics & Protocol Transparency Committee and the ISAR operational committee, ensuring the conduct of ethical, clinically relevant research that brings value to all key stakeholders.CONCLUSIONS: ISAR aims to offer a rich source of real-life data for scientific research to understand and improve disease burden, treatment patterns and patient outcomes in severe asthma. Furthermore, the registry will provide an international platform for research collaboration in respiratory medicine, with the overarching aim of improving primary and secondary care of adults with severe asthma globally.",
author = "FitzGerald, {J Mark} and Tran, {Trung N} and Marianna Alacqua and Alan Altraja and Vibeke Backer and Leif Bjermer and Unnur Bjornsdottir and Arnaud Bourdin and Guy Brusselle and Lakmini Bulathsinhala and John Busby and Canonica, {Giorgio W} and Victoria Carter and Isha Chaudhry and Cho, {You Sook} and George Christoff and Cosio, {Borja G} and Costello, {Richard W} and Neva Eleangovan and Gibson, {Peter G} and Heaney, {Liam G} and Enrico Heffler and Mark Hew and Naeimeh Hosseini and Takashi Iwanaga and Jackson, {David J} and Rupert Jones and Koh, {Mariko S} and Thao Le and Lauri Lehtim{\"a}ki and Dora Ludviksdottir and {Maitland-van der Zee}, {Anke H} and Andrew Menzies-Gow and Murray, {Ruth B} and Papadopoulos, {Nikolaos G} and Luis Perez-de-Llano and Matthew Peters and Pfeffer, {Paul E} and Popov, {Todor A} and Porsbjerg, {Celeste M} and Price, {Chris A} and Rhee, {Chin K} and Mohsen Sadatsafavi and Yuji Tohda and Eileen Wang and Wechsler, {Michael E} and James Zangrilli and Price, {David B}",
year = "2020",
month = "8",
day = "14",
doi = "10.1186/s12874-020-01065-0",
language = "English",
volume = "20",
pages = "212",
journal = "BMC Medical Research Methodology",
issn = "1471-2288",
publisher = "BioMed Central Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - International severe asthma registry (ISAR)

T2 - protocol for a global registry

AU - FitzGerald, J Mark

AU - Tran, Trung N

AU - Alacqua, Marianna

AU - Altraja, Alan

AU - Backer, Vibeke

AU - Bjermer, Leif

AU - Bjornsdottir, Unnur

AU - Bourdin, Arnaud

AU - Brusselle, Guy

AU - Bulathsinhala, Lakmini

AU - Busby, John

AU - Canonica, Giorgio W

AU - Carter, Victoria

AU - Chaudhry, Isha

AU - Cho, You Sook

AU - Christoff, George

AU - Cosio, Borja G

AU - Costello, Richard W

AU - Eleangovan, Neva

AU - Gibson, Peter G

AU - Heaney, Liam G

AU - Heffler, Enrico

AU - Hew, Mark

AU - Hosseini, Naeimeh

AU - Iwanaga, Takashi

AU - Jackson, David J

AU - Jones, Rupert

AU - Koh, Mariko S

AU - Le, Thao

AU - Lehtimäki, Lauri

AU - Ludviksdottir, Dora

AU - Maitland-van der Zee, Anke H

AU - Menzies-Gow, Andrew

AU - Murray, Ruth B

AU - Papadopoulos, Nikolaos G

AU - Perez-de-Llano, Luis

AU - Peters, Matthew

AU - Pfeffer, Paul E

AU - Popov, Todor A

AU - Porsbjerg, Celeste M

AU - Price, Chris A

AU - Rhee, Chin K

AU - Sadatsafavi, Mohsen

AU - Tohda, Yuji

AU - Wang, Eileen

AU - Wechsler, Michael E

AU - Zangrilli, James

AU - Price, David B

PY - 2020/8/14

Y1 - 2020/8/14

N2 - BACKGROUND: Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the heterogeneity of the severe asthma population, many patients need to be evaluated to understand the clinical features and outcomes of severe asthma in order to facilitate personalised and targeted care. The International Severe Asthma Registry (ISAR) is a multi-country registry project initiated to aid in this endeavour.METHODS: ISAR is a multi-disciplinary initiative benefitting from the combined experience of the ISAR Steering Committee (ISC; comprising 47 clinicians and researchers across 29 countries, who have a special interest and/or experience in severe asthma management or establishment and maintenance of severe asthma registries) in collaboration with scientists and experts in database management and communication. Patients (≥18 years old) receiving treatment according to the 2018 definitions of the Global Initiative for Asthma (GINA) Step 5 or uncontrolled on GINA Step 4 treatment will be included. Data will be collected on a core set of 95 variables identified using the Delphi method. Participating registries will agree to provide access to and share standardised anonymous patient-level data with ISAR. ISAR is a registered data source on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ISAR's collaborators include Optimum Patient Care, the Respiratory Effectiveness Group (REG) and AstraZeneca. ISAR is overseen by the ISC, REG, the Anonymised Data Ethics & Protocol Transparency Committee and the ISAR operational committee, ensuring the conduct of ethical, clinically relevant research that brings value to all key stakeholders.CONCLUSIONS: ISAR aims to offer a rich source of real-life data for scientific research to understand and improve disease burden, treatment patterns and patient outcomes in severe asthma. Furthermore, the registry will provide an international platform for research collaboration in respiratory medicine, with the overarching aim of improving primary and secondary care of adults with severe asthma globally.

AB - BACKGROUND: Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the heterogeneity of the severe asthma population, many patients need to be evaluated to understand the clinical features and outcomes of severe asthma in order to facilitate personalised and targeted care. The International Severe Asthma Registry (ISAR) is a multi-country registry project initiated to aid in this endeavour.METHODS: ISAR is a multi-disciplinary initiative benefitting from the combined experience of the ISAR Steering Committee (ISC; comprising 47 clinicians and researchers across 29 countries, who have a special interest and/or experience in severe asthma management or establishment and maintenance of severe asthma registries) in collaboration with scientists and experts in database management and communication. Patients (≥18 years old) receiving treatment according to the 2018 definitions of the Global Initiative for Asthma (GINA) Step 5 or uncontrolled on GINA Step 4 treatment will be included. Data will be collected on a core set of 95 variables identified using the Delphi method. Participating registries will agree to provide access to and share standardised anonymous patient-level data with ISAR. ISAR is a registered data source on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ISAR's collaborators include Optimum Patient Care, the Respiratory Effectiveness Group (REG) and AstraZeneca. ISAR is overseen by the ISC, REG, the Anonymised Data Ethics & Protocol Transparency Committee and the ISAR operational committee, ensuring the conduct of ethical, clinically relevant research that brings value to all key stakeholders.CONCLUSIONS: ISAR aims to offer a rich source of real-life data for scientific research to understand and improve disease burden, treatment patterns and patient outcomes in severe asthma. Furthermore, the registry will provide an international platform for research collaboration in respiratory medicine, with the overarching aim of improving primary and secondary care of adults with severe asthma globally.

U2 - 10.1186/s12874-020-01065-0

DO - 10.1186/s12874-020-01065-0

M3 - Journal article

VL - 20

SP - 212

JO - BMC Medical Research Methodology

JF - BMC Medical Research Methodology

SN - 1471-2288

IS - 1

ER -

ID: 60804841